Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.52 |
| ▸ | LPL | P06858 | 12/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | F11 | P03951 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456009 | 0.81 | LPL (0.49) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL17863581 | 0.81 | MAPK1 (0.37) | — | |
| SCHEMBL228212 | 0.81 | LPL (0.71) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL20513152 | 0.79 | NPC1 (0.48) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL16783747 | 0.79 | LIPG (0.47) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL14804365 | 0.77 | LPL (0.52) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL16112310 | 0.77 | LPL (0.52) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL19861982 | 0.76 | LIPG (0.65) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL661288 | 0.75 | LPL (0.59) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL24608995 | 0.74 | LIPG (0.83) | LIPGLPLCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240366772-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12059470-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240082407-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2024-03-14 | — | — | US | disclosed |
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4211144-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING PD-1 ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | Nammi Therapeutics, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3986896-B1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-20220080051-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022055542-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING PD-1 ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | NAMMI THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |
| EP-3083617-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
| WO-2012076886-A2 | NOVEL PROCESS AND COMPOUNDS | THE UNIVERSITY OF MANCHESTER (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082407-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | LIPG 65/4885LPL 51/4885CA1 3480/4885 |
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | LIPG 65/4885LPL 51/4885CA1 3480/4885 |
| US-20240366772-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | CD274, PDCD1LG2, PDCD1 | LIPG 65/4885LPL 51/4885CA1 3480/4885 |
| US-20220080051-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | LIPG 65/4885LPL 51/4885CA1 3480/4885 |
| US-12059470-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | LIPG 65/4885LPL 51/4885CA1 3480/4885 |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | LIPG 1876/4885LPL 4544/4885CA1 4860/4885 |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIKFYVE, IP6K2, IP6K3 | LIPG 1580/4885LPL 3498/4885CA1 4262/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | LIPG 1994/4885LPL 4600/4885CA1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.